Top

Published in:

01-06-2015 | Leading Article

Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date

Authors: Lawrence K. Fung, Antonio Y. Hardan

Published in: CNS Drugs | Issue 6/2015

Abstract

Pharmacologic treatments targeting specific molecular mechanisms relevant for autism spectrum disorder (ASD) are beginning to emerge in early drug development. This article reviews the evidence for the disruption of glutamatergic neurotransmission in animal models of social deficits and summarizes key pre-clinical and clinical efforts in developing pharmacologic interventions based on modulation of glutamatergic systems in individuals with ASD. Understanding the pathobiology of the glutamatergic system has led to the development of new investigational treatments for individuals with ASD. Specific examples of medications that modulate the glutamatergic system in pre-clinical and clinical studies are described. Finally, we discuss the limitations of current strategies and future opportunities in developing medications targeting the glutamatergic system for treating individuals with ASD.

CDC. Prevalence of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 sites, United States, 2010. Morb Mortal Wkly Rep Surveill Summ. 2014;63(Suppl 2):1–21.

De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Ercument Cicek A, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature. 2014;515(7526):209–15.PubMedCentralPubMedCrossRef

Rubenstein JL, Merzenich MM. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2003;2(5):255–67.PubMedCrossRef

Purcell AE, Jeon OH, Zimmerman AW, Blue ME, Pevsner J. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology. 2001;57(9):1618–28.PubMedCrossRef

Fatemi SH, Folsom TD, Kneeland RE, Liesch SB. Metabotropic glutamate receptor 5 upregulation in children with autism is associated with underexpression of both fragile X mental retardation protein and GABA(A) receptor beta 3 in adults with autism. Anat Rec (Hoboken). 2011;294(10):1635–45.CrossRef

Aldred S, Moore KM, Fitzgerald M, Waring RH. Plasma amino acid levels in children with autism and their families. J Autism Dev Disord. 2003;33(1):93–7.PubMedCrossRef

Tirouvanziam R, Obukhanych TV, Laval J, Aronov PA, Libove R, Banerjee AG, et al. Distinct plasma profile of polar neutral amino acids, leucine, and glutamate in children with autism spectrum disorders. J Autism Dev Disord. 2012;42(5):827–36.PubMedCrossRef

Shimmura C, Suda S, Tsuchiya KJ, Hashimoto K, Ohno K, Matsuzaki H, et al. Alteration of plasma glutamate and glutamine levels in children with high-functioning autism. PLoS One. 2011;6(10):e25340.PubMedCentralPubMedCrossRef

Shinohe A, Hashimoto K, Nakamura K, Tsujii M, Iwata Y, Tsuchiya KJ, et al. Increased serum levels of glutamate in adult patients with autism. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(8):1472–7.PubMedCrossRef

10.

Page LA, Daly E, Schmitz N, Simmons A, Toal F, Deeley Q, et al. In vivo 1H-magnetic resonance spectroscopy study of amygdala-hippocampal and parietal regions in autism. Am J Psychiatry. 2006;163(12):2189–92.PubMed

11.

Joshi G, Biederman J, Wozniak J, Goldin RL, Crowley D, Furtak S, et al. Magnetic resonance spectroscopy study of the glutamatergic system in adolescent males with high-functioning autistic disorder: a pilot study at 4T. Eur Arch Psychiatry Clin Neurosci. 2013;263(5):379–84.PubMedCrossRef

12.

Bejjani A, O’Neill J, Kim JA, Frew AJ, Yee VW, Ly R, et al. Elevated glutamatergic compounds in pregenual anterior cingulate in pediatric autism spectrum disorder demonstrated by 1H MRS and 1H MRSI. PLoS One. 2012;7(7):e38786.PubMedCentralPubMedCrossRef

13.

Brown MS, Singel D, Hepburn S, Rojas DC. Increased glutamate concentration in the auditory cortex of persons with autism and first-degree relatives: a (1)H-MRS study. Autism Res. 2013;6(1):1–10.PubMedCentralPubMedCrossRef

14.

Bernardi S, Anagnostou E, Shen J, Kolevzon A, Buxbaum JD, Hollander E, et al. In vivo 1H-magnetic resonance spectroscopy study of the attentional networks in autism. Brain Res. 2011;22(1380):198–205.CrossRef

15.

Hardan AY, Minshew NJ, Melhem NM, Srihari S, Jo B, Bansal R, et al. An MRI and proton spectroscopy study of the thalamus in children with autism. Psychiatry Res. 2008;163(2):97–105.PubMedCentralPubMedCrossRef

16.

Doyle-Thomas KA, Card D, Soorya LV, Wang AT, Fan J, Anagnostou E. Metabolic mapping of deep brain structures and associations with symptomatology in autism spectrum disorders. Res Autism Spectr Disord. 2014;8(1):44–51.PubMedCentralPubMedCrossRef

17.

Kubas B, Kulak W, Sobaniec W, Tarasow E, Lebkowska U, Walecki J. Metabolite alterations in autistic children: a 1H MR spectroscopy study. Adv Med Sci. 2012;57(1):152–6.PubMedCrossRef

18.

Rojas DC. The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment. J Neural Transm. 2014;121(8):891–905.PubMedCrossRef

19.

Buttenschon HN, Lauritsen MB, El Daoud A, Hollegaard M, Jorgensen M, Tvedegaard K, et al. A population-based association study of glutamate decarboxylase 1 as a candidate gene for autism. J Neural Transm. 2009;116(3):381–8.PubMedCrossRef

20.

Chang SC, Pauls DL, Lange C, Sasanfar R, Santangelo SL. Common genetic variation in the GAD1 gene and the entire family of DLX homeobox genes and autism spectrum disorders. Am J Med Genet B Neuropsychiatr Genet. 2011;156(2):233–9.PubMedCentralPubMedCrossRef

21.

O’Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature. 2012;485(7397):246–50.PubMedCentralPubMedCrossRef

22.

Sudhof TC. Neuroligins and neurexins link synaptic function to cognitive disease. Nature. 2008;455(7215):903–11.PubMedCentralPubMedCrossRef

23.

Talebizadeh Z, Bittel DC, Veatch OJ, Butler MG, Takahashi TN, Miles JH. Do known mutations in neuroligin genes (NLGN3 and NLGN4) cause autism? J Autism Dev Disord. 2004;34(6):735–6.PubMedCrossRef

24.

Gauthier J, Bonnel A, St-Onge J, Karemera L, Laurent S, Mottron L, et al. NLGN3/NLGN4 gene mutations are not responsible for autism in the Quebec population. Am J Med Genet B Neuropsychiatr Genet. 2005;132B(1):74–5.PubMedCrossRef

25.

Foldy C, Malenka RC, Sudhof TC. Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling. Neuron. 2013;78(3):498–509.PubMedCentralPubMedCrossRef

26.

Jamain S, Quach H, Betancur C, Rastam M, Colineaux C, Gillberg IC, et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet. 2003;34(1):27–9.PubMedCentralPubMedCrossRef

27.

Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, et al. X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. Am J Hum Genet. 2004;74(3):552–7.PubMedCentralPubMedCrossRef

28.

Autism Genome Project C, Szatmari P, Paterson AD, Zwaigenbaum L, Roberts W, Brian J, et al. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet. 2007;39(3):319–28.CrossRef

29.

Bremer A, Giacobini M, Eriksson M, Gustavsson P, Nordin V, Fernell E, et al. Copy number variation characteristics in subpopulations of patients with autism spectrum disorders. Am J Med Genet B Neuropsychiatr Genet. 2011;156(2):115–24.PubMedCrossRef

30.

Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R, et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature. 2010;466(7304):368–72.PubMedCentralPubMedCrossRef

31.

Gauthier J, Siddiqui TJ, Huashan P, Yokomaku D, Hamdan FF, Champagne N, et al. Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia. Hum Genet. 2011;130(4):563–73.PubMedCentralPubMedCrossRef

32.

Vaags AK, Lionel AC, Sato D, Goodenberger M, Stein QP, Curran S, et al. Rare deletions at the neurexin 3 locus in autism spectrum disorder. Am J Hum Genet. 2012;90(1):133–41.PubMedCentralPubMedCrossRef

33.

Strauss KA, Puffenberger EG, Huentelman MJ, Gottlieb S, Dobrin SE, Parod JM, et al. Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2. N Engl J Med. 2006;354(13):1370–7.PubMedCrossRef

34.

Bakkaloglu B, O’Roak BJ, Louvi A, Gupta AR, Abelson JF, Morgan TM, et al. Molecular cytogenetic analysis and resequencing of contactin associated protein-like 2 in autism spectrum disorders. Am J Hum Genet. 2008;82(1):165–73.PubMedCentralPubMedCrossRef

35.

Alarcon M, Abrahams BS, Stone JL, Duvall JA, Perederiy JV, Bomar JM, et al. Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. Am J Hum Genet. 2008;82(1):150–9.PubMedCentralPubMedCrossRef

36.

Sampath S, Bhat S, Gupta S, O’Connor A, West AB, Arking DE, et al. Defining the contribution of CNTNAP2 to autism susceptibility. PLoS One. 2013;8(10):e77906.PubMedCentralPubMedCrossRef

37.

Meyer D, Bonhoeffer T, Scheuss V. Balance and stability of synaptic structures during synaptic plasticity. Neuron. 2014;82(2):430–43.PubMedCrossRef

38.

Sheng M, Sala C. PDZ domains and the organization of supramolecular complexes. Annu Rev Neurosci. 2001;24:1–29.PubMedCrossRef

39.

Feyder M, Karlsson RM, Mathur P, Lyman M, Bock R, Momenan R, et al. Association of mouse Dlg4 (PSD-95) gene deletion and human DLG4 gene variation with phenotypes relevant to autism spectrum disorders and Williams’ syndrome. Am J Psychiatry. 2010;167(12):1508–17.PubMedCentralPubMedCrossRef

40.

Wellmann KA, Varlinskaya EI, Mooney SM. d-Cycloserine ameliorates social alterations that result from prenatal exposure to valproic acid. Brain Res Bull. 2014;15(108C):1–9.CrossRef

41.

Deutsch SI, Pepe GJ, Burket JA, Winebarger EE, Herndon AL, Benson AD. d-Cycloserine improves sociability and spontaneous stereotypic behaviors in 4-week old mice. Brain Res. 2012;23(1439):96–107.CrossRef

42.

Modi ME, Young LJ. d-Cycloserine facilitates socially reinforced learning in an animal model relevant to autism spectrum disorders. Biol Psychiatry. 2011;70(3):298–304.PubMedCentralPubMedCrossRef

43.

Burket JA, Benson AD, Tang AH, Deutsch SI. d-Cycloserine improves sociability in the BTBR T+ Itpr3tf/J mouse model of autism spectrum disorders with altered Ras/Raf/ERK1/2 signaling. Brain Res Bull. 2013;96:62–70.PubMedCrossRef

44.

Won H, Lee HR, Gee HY, Mah W, Kim JI, Lee J, et al. Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature. 2012;486(7402):261–5.PubMedCrossRef

45.

Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougle CJ. A pilot study of d-cycloserine in subjects with autistic disorder. Am J Psychiatry. 2004;161(11):2115–7.PubMedCrossRef

46.

Urbano M, Okwara L, Manser P, Hartmann K, Herndon A, Deutsch SI. A trial of d-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder. Clin Neuropharmacol. 2014;37(3):69–72.PubMedCentralPubMedCrossRef

47.

Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, et al. Amantadine extended release for levodopa-induced dyskinesia in Parkinson’s disease (EASED Study). Mov Disord. 2015;30(6):788–95.PubMedCrossRef

48.

King BH, Wright DM, Handen BL, Sikich L, Zimmerman AW, McMahon W, et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001;40(6):658–65.PubMedCrossRef

49.

Wilkinson D, Wirth Y, Goebel C. Memantine in patients with moderate to severe Alzheimer’s disease: meta-analyses using realistic definitions of response. Dement Geriatr Cogn Disord. 2014;37(1–2):71–85.PubMedCrossRef

50.

Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology. 2007;191(1):141–7.PubMedCrossRef

51.

Owley T, Salt J, Guter S, Grieve A, Walton L, Ayuyao N, et al. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16(5):517–24.PubMedCrossRef

52.

Forest Laboratories. Safety study of memantine in pediatric patients with autism, Asperger’s disorder or pervasive developmental disorder not otherwise specified (PDD-NOS) [ClinicalTrials.gov identifier NCT01592773]. US National Institutes of Health, ClinicalTrials.gov. 2015. http://www.clinicaltrials.gov. Accessed 29 May 2015.

53.

Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996;47(6 Suppl 4):S233–41.PubMedCrossRef

54.

Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;3:CD001447. Accessed May 29 2015.PubMed

55.

Wink LK, Erickson CA, Stigler KA, McDougle CJ. Riluzole in autistic disorder. J Child Adolesc Psychopharmacol. 2011;21(4):375–9.PubMedCrossRef

56.

Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;9:CD004332.PubMed

57.

Erickson CA, Wink LK, Early MC, Stiegelmeyer E, Mathieu-Frasier L, Patrick V, et al. Brief report: pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder. J Autism Dev Disord. 2014;44(4):981–7.PubMedCrossRef

58.

Angehagen M, Ronnback L, Hansson E, Ben-Menachem E. Topiramate reduces AMPA-induced Ca(2+) transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures. J Neurochem. 2005;94(4):1124–30.PubMedCrossRef

59.

Hardan AY, Jou RJ, Handen BL. A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004;14(3):426–32.PubMedCrossRef

60.

Reiss AL, Dant CC. The behavioral neurogenetics of fragile X syndrome: analyzing gene-brain-behavior relationships in child developmental psychopathologies. Dev Psychopathol. 2003;15(4):927–68.PubMedCrossRef

61.

Freund LS, Reiss AL. Cognitive profiles associated with the fra(X) syndrome in males and females. Am J Med Genet. 1991;38(4):542–7.PubMedCrossRef

62.

Hill MK, Archibald AD, Cohen J, Metcalfe SA. A systematic review of population screening for fragile X syndrome. Genet Med. 2010;12(7):396–410.PubMedCrossRef

63.

Wheeler AC, Mussey J, Villagomez A, Bishop E, Raspa M, Edwards A, et al. DSM-5 changes and the prevalence of parent-reported autism spectrum symptoms in Fragile X syndrome. J Autism Dev Disord. 2015;45(3):816–29.PubMedCrossRef

64.

Feinstein C, Reiss AL. Autism: the point of view from fragile X studies. J Autism Dev Disord. 1998;28(5):393–405.PubMedCrossRef

65.

Kau AS, Tierney E, Bukelis I, Stump MH, Kates WR, Trescher WH, et al. Social behavior profile in young males with fragile X syndrome: characteristics and specificity. Am J Med Genet A. 2004;126A(1):9–17.PubMedCrossRef

66.

Van der Molen MJ, Huizinga M, Huizenga HM, Ridderinkhof KR, Van der Molen MW, Hamel BJ, et al. Profiling fragile X Syndrome in males: strengths and weaknesses in cognitive abilities. Res Dev Disabil. 2010;31(2):426–39.PubMedCrossRef

67.

Feinstein C, Singh S. Social phenotypes in neurogenetic syndromes. Child Adolesc Psychiatr Clin N Am. 2007;16(3):631–47.PubMedCrossRef

68.

Gantois I, Pop AS, de Esch CE, Buijsen RA, Pooters T, Gomez-Mancilla B, et al. Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice. Behav Brain Res. 2013;15(239):72–9.CrossRef

69.

Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med. 2011;3(64):64ra1.PubMedCrossRef

70.

Jaeschke G, Kolczewski S, Spooren W, Vieira E, Bitter-Stoll N, Boissin P, et al. Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (Basimglurant, RO4917523), a promising novel medicine for psychiatric diseases. J Med Chem. 2015;58(3):1358–71.PubMedCrossRef

71.

Grant JE, Odlaug BL, Kim SW. N-Acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2009;66(7):756–63.PubMedCrossRef

72.

Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-Acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008;64(6):468–75.PubMedCrossRef

73.

Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-Acetyl cysteine as a glutathione precursor for schizophrenia—a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64(5):361–8.PubMedCrossRef

74.

Hardan AY, Fung LK, Libove RA, Obukhanych TV, Nair S, Herzenberg LA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry. 2012;71(11):956–61.PubMedCrossRef

75.

RUPP. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314–21.CrossRef

76.

Javitt DC, Schoepp D, Kalivas PW, Volkow ND, Zarate C, Merchant K, et al. Translating glutamate: from pathophysiology to treatment. Sci Transl Med. 2011;3(102):102mr2.PubMedCentralPubMedCrossRef

77.

Wolff JJ, Gu H, Gerig G, Elison JT, Styner M, Gouttard S, et al. Differences in white matter fiber tract development present from 6 to 24 months in infants with autism. Am J Psychiatry. 2012;169(6):589–600.PubMedCentralPubMedCrossRef

78.

Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363–72.PubMedCrossRef

79.

Nithianantharajah J, Hannan AJ. Enriched environments, experience-dependent plasticity and disorders of the nervous system. Nat Rev Neurosci. 2006;7(9):697–709.PubMedCrossRef

80.

Restivo L, Ferrari F, Passino E, Sgobio C, Bock J, Oostra BA, et al. Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. Proc Natl Acad Sci USA. 2005;102(32):11557–62.PubMedCentralPubMedCrossRef

81.

Pagnamenta AT, Khan H, Walker S, Gerrelli D, Wing K, Bonaglia MC, et al. Rare familial 16q21 microdeletions under a linkage peak implicate cadherin 8 (CDH8) in susceptibility to autism and learning disability. J Med Genet. 2011;48(1):48–54.PubMedCentralPubMedCrossRef

82.

Wang K, Zhang H, Ma D, Bucan M, Glessner JT, Abrahams BS, et al. Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature. 2009;459(7246):528–33.PubMedCentralPubMedCrossRef

83.

Sanders SJ, Ercan-Sencicek AG, Hus V, Luo R, Murtha MT, Moreno-De-Luca D, et al. Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron. 2011;70(5):863–85.PubMedCentralPubMedCrossRef

84.

Grau C, Arato K, Fernandez-Fernandez JM, Valderrama A, Sindreu C, Fillat C, et al. DYRK1A-mediated phosphorylation of GluN2A at Ser (1048) regulates the surface expression and channel activity of GluN1/GluN2A receptors. Front Cell Neurosci. 2014;8:331.PubMedCentralPubMedCrossRef

85.

Betancur C, Sakurai T, Buxbaum JD. The emerging role of synaptic cell-adhesion pathways in the pathogenesis of autism spectrum disorders. Trends Neurosci. 2009;32(7):402–12.PubMedCrossRef

86.

Ramoz N, Reichert JG, Smith CJ, Silverman JM, Bespalova IN, Davis KL, et al. Linkage and association of the mitochondrial aspartate/glutamate carrier SLC25A12 gene with autism. Am J Psychiatry. 2004;161(4):662–9.PubMedCrossRef

87.

Gauthier J, Spiegelman D, Piton A, Lafreniere RG, Laurent S, St-Onge J, et al. Novel de novo SHANK3 mutation in autistic patients. Am J Med Genet B Neuropsychiatr Genet. 2009;150B(3):421–4.PubMedCrossRef

88.

Gauthier J, Champagne N, Lafreniere RG, Xiong L, Spiegelman D, Brustein E, et al. De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. Proc Natl Acad Sci USA. 2010;107(17):7863–8.PubMedCentralPubMedCrossRef

89.

Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F, et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet. 2007;39(1):25–7.PubMedCentralPubMedCrossRef

90.

Berkel S, Marshall CR, Weiss B, Howe J, Roeth R, Moog U, et al. Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation. Nat Genet. 2010;42(6):489–91.PubMedCrossRef

91.

Sato D, Lionel AC, Leblond CS, Prasad A, Pinto D, Walker S, et al. SHANK1 deletions in males with autism spectrum disorder. Am J Hum Genet. 2012;90(5):879–87.PubMedCentralPubMedCrossRef

92.

Guilmatre A, Huguet G, Delorme R, Bourgeron T. The emerging role of SHANK genes in neuropsychiatric disorders. Dev Neurobiol. 2014;74(2):113–22.PubMedCrossRef

93.

Fassio A, Patry L, Congia S, Onofri F, Piton A, Gauthier J, et al. SYN1 loss-of-function mutations in autism and partial epilepsy cause impaired synaptic function. Hum Mol Genet. 2011;20(12):2297–307.PubMedCrossRef

94.

Corradi A, Fadda M, Piton A, Patry L, Marte A, Rossi P, et al. SYN2 is an autism predisposing gene: loss-of-function mutations alter synaptic vesicle cycling and axon outgrowth. Hum Mol Genet. 2014;23(1):90–103.PubMedCentralPubMedCrossRef

95.

Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, et al. Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med. 2008;358(7):667–75.PubMedCrossRef

Title: Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date
Authors: Lawrence K. Fung
Antonio Y. Hardan
Publication date: 01-06-2015
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 6/2015
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.1007/s40263-015-0252-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2015

Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients

Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson’s Disease

Oxycodone/Naloxone PR: A Review in Severe Refractory Restless Legs Syndrome

Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials

Targeting CGRP: A New Era for Migraine Treatment

Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations